- Home
- Solutions
- By Diseases
- Ocular Neoplastic Diseases
- Choroidal Hemangioma
Choroidal hemangioma is a relatively rare, benign vascular tumor of the choroid, the highly vascular middle layer of the eye responsible for nourishing the retina. Protheragen, a leading research services provider with expertise in ophthalmic diseases, offers clients specialized choroidal hemangioma diagnostics and therapeutic development services.
Choroidal hemangioma is defined as a benign vascular tumor that arises from the choroid that lies in between the retina and the sclera. There are two forms of this tumor: circumscribed choroidal hemangioma (CCH) and diffuse choroidal hemangioma (DCH). CCH appears to be a single oval salmon-red mass that is posterior to the eye equator, most commonly in the macular or peripapillary regions. It is most often unilateral and, with time, becomes asymptomatic. On the other hand, DCH is more diffuse, ill-defined, and usually associated with Sturge-Weber syndrome and involves more than half of the choroid. DCH presents at birth and is characterized by its diffuse ill-defined borders.
Fig.1 Pathological analysis of capillary hemangioma. (Frossard J. C., et al., 2020)Effective identification of choroidal hemangioma is required be differentiated from other intraocular lesions, which include choroidal nevus, amelanotic choroidal melanoma, choroidal metastasis, choroidal osteoma, central serous chorioretinopathy, posterior scleritis. For the correct differentiation, examination, and imaging studies are always necessary. Choroidal metastasis is characteristically identified as creamy yellow lesions and differs in imaging appearance from choroidal hemangiomas.
Anti-VEGF Agents
Some anti-VEGF agents have been effective in decreasing subretinal and intraretinal fluids in certain cases suffering from choroidal hemangioma. For instance, studies focus on the effect of intravitreal injections of bevacizumab which have reported improvement of visual acuity and resolution of subretinal fluid in eyes with choroidal hemangiomas.
Oral Propranolol
A case report documented oral propranolol having the capacity to induce vasoconstriction and subsequently improving visual acuity through thickening of the tumor. While this offers a new strategy for treating choroidal hemangiomas, efficacy and safety testing still has to be performed.
Protheragen prides itself on providing specialized services catered to the needs of our clientele. Our team is ready to assist with high-quality, specialized solutions, whether you need help with diagnostics, therapeutics development, or preclinical research services.
In Vitro Models: Our research includes the use of cell models and organoid models to investigate the molecular mechanisms of choroidal hemangioma and screen potential therapeutic compounds.
In Vivo Models: We use animal models to assess the pharmacokinetics, pharmacodynamics, and toxicity of new therapeutic agents. These studies provide critical data for the development of effective therapeutics for choroidal hemangioma.
Through comprehensive diagnostics, novel therapies, and intensive preclinical studies, Protheragen works towards developing the therapy of choroidal hemangioma. We have the necessary infrastructure and know how to offer the best and most appropriate solutions to our clients. If you are interested in our services, please feel free to contact us.
Reference
Copyright © Protheragen. All rights reserved.